CD33 and acute myeloid leukemia: Recent preclinical studies have shown that the Auger-emitter 111In labeled to mAbs targeting CD33 and CD123 and conjugated to short peptides harboring a nuclear localization signal sequence could kill AML cell lines and primary AML cell engrafted into mice.